The funds will go toward the Kinder Institute's civic data initiatives. Photo via news.rice.edu

The Houston Endowment has renewed its support of Rice University's Kinder Institute for Urban Research with a $2.25 million three-year grant to expand its services relating to urban data collection and use.

"We are immensely grateful to Houston Endowment for its continued support of Rice and the Kinder Institute," Rice President David Leebron says in a release. "This renewed funding will allow the institute to continue its critical data-driven work to better understand the challenges that Houston and other cities are facing and create lasting solutions. Contributing to our home city and others in this way is central to Rice's mission and its strategic plan, and we are extremely appreciative of this generous support."

In addition to supporting the Kinder Institute's data tools, the funding will contribute to the Houston Urban Data Project 2.0. The institute is involved in the project as is the Houston Community Data Connections, or HCDC. According to the release, the UDP will work to align and enhance urban and community data initiatives, develop training and research support for a larger user base, and raise awareness of the institute's research through outreach.

The HCDC, which was established in September of 2017, is already equipped to analyze 143 areas in Harris County with over 9,000 users, almost 16,000 site sessions, and over 45,000 page views, per the release. The program has seen 120 research and data requests since launch. Meanwhile, the UDP has 200 datasets in Houston and has 400 users who have accessed the site 6,000 times since it launched in the Spring of 2018

"The UDP and HCDC have laid the foundation for a shift in how data is used and decisions are made in the public, philanthropic and nonprofit sectors, and this funding will allow the Kinder Institute to build on this work," says Bill Fulton, director of the institute, in the release. "This project will help drive effective, data-driven decision-making for the region and will make the Kinder Institute the data hub for the entire region and a model for other cities around the world."

The purpose of the program will be two initiatives: Building Better Cities, which will focus on government efficiency and urban systems, and Building Better Lives, geared at quality of life and urban disparity among Houston residents.

"At Houston Endowment, our vision is a vibrant region where all have the opportunity to thrive," says Ann B. Stern, president and CEO of Houston Endowment, in the release. "We believe that making good data available to the public leads to better-informed decision-making on the part of our public officials and allows residents to more effectively advocate for their communities' needs. This is why the UDP and HCDC are so important for the future of our region."

The Kinder Institute, founded in 2010, is a research and advocate organization for urban development in Houston, and the Houston Endowment, established by Jesse H. and Mary Gibbs Jones in 1937, has assets of $1.8 billion and contributes around $70 million annually.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”